RT Journal Article
SR Electronic
T1 COVID-19 receptor ACE2 is expressed in human conjunctival tissue, expecially in diseased conjunctival
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.21.20109652
DO 10.1101/2020.05.21.20109652
A1 Li, Shengjie
A1 Li, Danhui
A1 Fang, Jianchen
A1 Liu, Qiang
A1 Sun, Xinghuai
A1 Xu, Gezhi
A1 Cao, Wenjun
YR 2020
UL http://medrxiv.org/content/early/2020/05/23/2020.05.21.20109652.abstract
AB COVID-19 virus has currently caused major outbreaks worldwide. ACE2 is a major cellular-entry receptor for the COVID-19 virus. Although ACE2 is known to be expressed in many organs, whether it is expressed by the conjunctival tissue is largely unknown. Human conjunctival tissues from 68 subjects were obtained, which included 10 subjects with conjunctival nevi, 20 subjects with conjunctivitis, 9 subjects with conjunctival papilloma, 16 subjects with conjunctival cyst, 7 subjects with conjunctival polyps, and 6 ocular traumas as normal subjects. Expression of ACE2 was evaluated by immunohistochemistry, immunofluorescence, reverse transcriptase-quantitative polymerase chain reaction, and western blot assay. We observed the expression of ACE2 by conjunctival tissues, expecially in conjunctival epithelial cells. ACE2 was significantly (p<0.001) overexpressed in conjunctival cells obtained from subjects with conjunctivitis, conjunctival nevi, conjunctival papilloma, conjunctival cyst, and conjunctival polyps epithelial cells when compared to that in conjunctival epithelial cells obtained from control subjects. Collectively, clinical features of reported COVID-19 patients combined with our results indicate that COVID-19 is likely to be transmitted through the conjunctiva.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Shanghai Sailing Program (18YF1403500), Shanghai Municipal Commission of Health and Family Planning (20174Y0169), Shanghai Municipal Commission of Health and Family Planning (201840050), Shanghai Science Technology Committee Foundation grant (19411964600).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Renji Hospital of Shanghai Jiao Tong University approved this study, and it adhered to the principles of the Declaration of Helsinki. Informed consent was obtained from all participating subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data has been shown in manuscript.